Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Medical Devices Pipeline Assessment, 2017

Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) uses an Implantable Cardioverter Defibrillator (ICD) to improve the coordination of the heart rhythm. This device utilizes three leads, one to the right atrium and one in each of the ventricles. GlobalData's Medical Devices sector report, “Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Medical Devices Pipeline Assessment, 2017" provides comprehensive information about the Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Scope

The Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Pipeline Assessment report provides key information and data related to:

• Extensive coverage of the Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) under development.

• Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates.

• Reviews of major players involved in the pipeline product development.

• Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) pipeline products.

• Review of recent developments in the segment / industry.

Reasons to buy

The Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Pipeline Assessment report enables you to:

• Access significant competitor information, analysis, and insights to improve your R&D strategies.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Identify and understand important and diverse types of Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) under development.

• Formulate market-entry and market expansion strategies.

• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

Companies mentioned

Boston Scientific Corp

IRadimed Corp

John Hopkins University

LivaNova PLC

Mayo Clinic US

Medtronic plc

NewPace Ltd

St. Jude Medical LLC

TransWorld Med Corp

Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Overview 7

3 Products under Development 8

3.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 8

3.2 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Segment 9

3.3 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Territory 10

3.4 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Regulatory Path 11

3.5 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Estimated Approval Date 12

3.6 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Ongoing Clinical Trials 13

4 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products under Development by Companies 14

4.1 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Companies – Pipeline Products by Stage of Development 14

4.2 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 15

5 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Companies and Product Overview 16

5.1 Boston Scientific Corp Company Overview 16

5.1.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

5.2 IRadimed Corp Company Overview 22

5.2.1 IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 22

5.3 John Hopkins University Company Overview 23

5.3.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 23

5.4 LivaNova PLC Company Overview 24

5.4.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 24

5.5 Mayo Clinic US Company Overview 31

5.5.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 31

5.6 Medtronic plc Company Overview 32

5.6.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 32

5.7 NewPace Ltd Company Overview 37

5.7.1 NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 37

5.8 St. Jude Medical LLC Company Overview 40

5.8.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 40

5.9 TransWorld Med Corp Company Overview 43

5.9.1 TransWorld Med Corp Pipeline Products & Ongoing Clinical Trials Overview 43

6 Cardiac Resynchronisation Therapy – Defibrillators (CRT-D)- Recent Developments 44

6.1 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 44

6.2 May 16, 2017: LivaNova Announces Thad Huston as Chief Financial Officer 47

6.3 May 09, 2017: Boston Scientific Receives U.S. FDA Approval For Resonate Family Of High-Voltage Devices 47

6.4 May 03, 2017: LivaNova Reports First Quarter 2017 Results 48

6.5 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 49

6.6 Mar 31, 2017: LivaNova Announces Chief Financial Officer Resignation 50

6.7 Mar 31, 2017: LivaNova Reiterates Full-Year 2017 Guidance 50

6.8 Mar 16, 2017: NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife Battery Technology For Treatment Of Heart Failure 51

6.9 Mar 01, 2017: LivaNova Reports Fourth Quarter and Full-Year 2016 Results 51

6.10 Feb 27, 2017: New Analysis of Reverse Trial Shows Medtronic CRT Devices Cost-Effective, While Helping Patients with Mild Heart Failure Live Longer 54

6.11 Feb 23, 2017: LivaNova Announces Its Intent to Delist from London Stock Exchange 55

6.12 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 55

6.13 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 58

6.14 Feb 06, 2017: Boston scientific launches Resonate family of CRT-D devices in Europe 59

6.15 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 60

6.16 Feb 01, 2017: BIOTRONIK Introduces a Complete CRT Solution with the Ilivia Series 61

6.17 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 62

6.18 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 65

6.19 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 65

6.20 Nov 14, 2016: Medtronic Receives FDA Approval for Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator 66

6.21 Nov 02, 2016: LivaNova Announces CEO Transition: Damien McDonald to Succeed Andre-Michel Ballester 67

6.22 Nov 02, 2016: LivaNova Reports Third Quarter 2016 Results 68

6.23 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 69

6.24 Oct 26, 2016: Nihon Kohden Announces Consolidation and Relocation of Offices 71

6.25 Oct 24, 2016: St. Jude Medical Recalls Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy Defibrillators Due to Premature Battery Depletion 71

6.26 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 72

6.27 Oct 13, 2016: Medtronic Cardiac Devices Gain FDA Approval to Enable Patient Access to the Most Advanced Diagnostic Imaging 74

6.28 Oct 11, 2016: Experts Discuss Clinical Benefits of Closed Loop Stimulation at Heart Rhythm Congress 75

6.29 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 75

6.30 Sep 29, 2016: LivaNova Announces Half-Year Financial Report 76

6.31 Sep 28, 2016: Hill-Rom Adding More Than 100 Jobs In Central New York 85

6.32 Sep 22, 2016: LivaNova Launches Next Generation ICD and CRT-D Devices in the United States 86

6.33 Sep 19, 2016: Analysis Shows Positive Association Between Cardiac Resynchronization Therapy and Patients' Increased Adherence to Heart Failure Medication Regimens 86

6.34 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 87

6.35 Aug 29, 2016: Medtronic Technologies Improve Delivery Of Cardiac Resynchronization Therapy 88

6.36 Aug 25, 2016: ZOLL LifeVest Wearable Defibrillator Proven Safe and Effective in Largest German Registry 89

6.37 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 90

6.38 Aug 03, 2016: LivaNova Reports Second Quarter 2016 Results 93

6.39 Aug 01, 2016: LivaNova Names Chief Operating Officer 94

6.40 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 95

6.41 Jul 28, 2016: LivaNova Names Andrea L. Saia to its Board of Directors 97

6.42 Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results 97

6.43 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 99

6.44 Jul 06, 2016: LivaNova Sets Operating Model and Supporting Organization 99

6.45 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 100

6.46 Jun 23, 2016: St. Jude Medical Expands Its Heart Failure Portfolio with SyncAV CRT Technology, Providing Physicians Another Option for Managing Patients Not Responsive to Other Therapies 100

6.47 Jun 10, 2016: 97% One-year Survival for Patients at High Risk of Sudden Cardiac Death Prescribed the ZOLL LifeVest Wearable Defibrillator 102

6.48 Jun 09, 2016: BIOTRONIK Wins Cardiostim Innovation Award for Best Practice Improvement with MRI AutoDetect Feature 103

6.49 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 103

6.50 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 104

7 Appendix 105

7.1 Methodology 105

7.2 About GlobalData 108

7.3 Contact Us 108

7.4 Disclaimer 108

List of Tables

Table 1: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 8

Table 2: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Segment 9

Table 3: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Territory 10

Table 4: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Regulatory Path 11

Table 5: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Estimated Approval Date 12

Table 6: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Ongoing Clinical Trials 13

Table 7: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) Companies – Pipeline Products by Stage of Development 14

Table 8: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 15

Table 9: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

Table 22: IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 22

Table 25: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 23

Table 28: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 24

Table 41: Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 31

Table 44: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 55: NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 37

Table 60: St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 40

Table 66: TransWorld Med Corp Pipeline Products & Ongoing Clinical Trials Overview 43

Table 69: Glossary 107

List of Figures

Figure 1: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Stage of Development 8

Figure 2: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Segment 9

Figure 3: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Territory 10

Figure 4: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Regulatory Path 11

Figure 5: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Pipeline Products by Estimated Approval Date 12

Figure 6: Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) – Ongoing Clinical Trials 13

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports